Sandbox Reserved 1722
From Proteopedia
(Difference between revisions)
| Line 5: | Line 5: | ||
== G-Protein Coupled Receptors == | == G-Protein Coupled Receptors == | ||
| - | [https://proteopedia.org/wiki/index.php/G_protein-coupled_receptors G-protein coupled receptors | + | [https://proteopedia.org/wiki/index.php/G_protein-coupled_receptors G-protein coupled receptors](GCPRs) are a large family of cell surface membrane receptors. Once bound to a wide variety of extracellular ligands, GCPRs undergo a conformational change and relay information to intracellular secondary messengers <ref name="Thal">Thal, David M., et al. "Structural insights into G-protein-coupled receptor allostery." Nature, Nature Publishing Group, 04 July 2018, https://www.nature.com/articles/s41586-018-0259-z</ref>. This G protein activation results in a cellular response dependent on the ligand bound and location of the GPCR in the body. GCPRs can be broken down into five families: the rhodopsin family (class A), the secretin family (class B), the adhesion family, the glutamate family (class C), and the frizzled/taste family (class F) <ref name="Zhang">PMID: 26467290</ref>. All of the families have a similar transmembrane (TM) domain consisting of seven <scene name='90/904328/7tm_domain_pt_4/1'>α-helices</scene> complexed with intracellular G proteins. |
== Class A GCPRs == | == Class A GCPRs == | ||
| Line 15: | Line 15: | ||
The human itch GPCR, or Mas-related G-protein coupled receptor (MRGPR), is a Class A GPCR found in human sensory neurons and is responsible for the sensation of “itching” caused by skin irritation and diseases, insect bites, and hypersensitivity to certain drugs. MRGPR's are broken into 4 groups consisting of MRGPRX1, MRGPRX2, MRGPRX3, and MRGPRX4. MRGPRX4 is responsible for cholestatic itching, an intense itching felt during pregnancy on the soles of the feet and palms of hands. Meanwhile, MRGPRX2 regulates [https://en.wikipedia.org/wiki/Degranulation degranulation] and [https://en.wikipedia.org/wiki/Hypersensitivity#:~:text=Hypersensitivity%20(also%20called%20hypersensitivity%20reaction,may%20be%20damaging%20and%20uncomfortable. hypersensitivity] itch reactions <ref name="Cao">Cao, Can, et al. "Structure, function and pharmacology of human itch GPCRs." Nature, Nature Publishing Group, 17 November 2021, https://www.nature.com/articles/s41586-021-04126-6</ref>. These two, chiefly MRGPRX2, are often targets for drugs that result in mast cell degranulation and hypersensitivity side effects. In comparison to other Class A GPCRs, MRGPRX2 binds to an even wider range of ligands, including agonists such as cations and peptides. | The human itch GPCR, or Mas-related G-protein coupled receptor (MRGPR), is a Class A GPCR found in human sensory neurons and is responsible for the sensation of “itching” caused by skin irritation and diseases, insect bites, and hypersensitivity to certain drugs. MRGPR's are broken into 4 groups consisting of MRGPRX1, MRGPRX2, MRGPRX3, and MRGPRX4. MRGPRX4 is responsible for cholestatic itching, an intense itching felt during pregnancy on the soles of the feet and palms of hands. Meanwhile, MRGPRX2 regulates [https://en.wikipedia.org/wiki/Degranulation degranulation] and [https://en.wikipedia.org/wiki/Hypersensitivity#:~:text=Hypersensitivity%20(also%20called%20hypersensitivity%20reaction,may%20be%20damaging%20and%20uncomfortable. hypersensitivity] itch reactions <ref name="Cao">Cao, Can, et al. "Structure, function and pharmacology of human itch GPCRs." Nature, Nature Publishing Group, 17 November 2021, https://www.nature.com/articles/s41586-021-04126-6</ref>. These two, chiefly MRGPRX2, are often targets for drugs that result in mast cell degranulation and hypersensitivity side effects. In comparison to other Class A GPCRs, MRGPRX2 binds to an even wider range of ligands, including agonists such as cations and peptides. | ||
[[Image:Electro.PNG|250px|right|thumb|'''Figure 1''': Binding pocket of MRGPRX2 with Cortistatin. Two different binding pockets are present in MRGPRX2 and cortistatin interacts with both of them. <ref name="Cao"/>]] | [[Image:Electro.PNG|250px|right|thumb|'''Figure 1''': Binding pocket of MRGPRX2 with Cortistatin. Two different binding pockets are present in MRGPRX2 and cortistatin interacts with both of them. <ref name="Cao"/>]] | ||
| - | |||
==== Agonists ==== | ==== Agonists ==== | ||
===== Cation ===== | ===== Cation ===== | ||
| + | |||
[[Image: Zinc.PNG|250px|right|thumb|'''Figure 2''': Structure of R-Zinc 3573. A cationic ligand selected for binding to MRGPRX2. This ligand was used as a probe for MRGPRX2 function and stabilization for structure determination. <ref name="Yang">Yang, Fan, et al. "Structure, function and pharmacology of human itch receptor complexes." Nature, Nature Publishing Group, 17 November 2021, https://www.nature.com/articles/s41586-021-04077-y</ref>]] <scene name='90/904328/Zinc_pt_2/1'>(R)-Zinc-3573</scene> is a cation ligand that selectively binds to MRGPRX2. Its N-dimethyl is inserted into subpocket 1 of the binding cavity with aromatic amino acid residues Phe-170, Trp-243, and Phe-244. In this <scene name='90/904328/Ziz_pt_2/1'>cavity</scene>, N-dimethyl group on the ligand makes ion pairs with Asp-184 and Glu-164. The ligand is then stabilized by stacking its ring with Trp-248 and the Cys-168 to Cys-180 disulfide bond <ref name="Yang">Yang, Fan, et al. "Structure, function and pharmacology of human itch receptor complexes." Nature, Nature Publishing Group, 17 November 2021, https://www.nature.com/articles/s41586-021-04077-y</ref>. | [[Image: Zinc.PNG|250px|right|thumb|'''Figure 2''': Structure of R-Zinc 3573. A cationic ligand selected for binding to MRGPRX2. This ligand was used as a probe for MRGPRX2 function and stabilization for structure determination. <ref name="Yang">Yang, Fan, et al. "Structure, function and pharmacology of human itch receptor complexes." Nature, Nature Publishing Group, 17 November 2021, https://www.nature.com/articles/s41586-021-04077-y</ref>]] <scene name='90/904328/Zinc_pt_2/1'>(R)-Zinc-3573</scene> is a cation ligand that selectively binds to MRGPRX2. Its N-dimethyl is inserted into subpocket 1 of the binding cavity with aromatic amino acid residues Phe-170, Trp-243, and Phe-244. In this <scene name='90/904328/Ziz_pt_2/1'>cavity</scene>, N-dimethyl group on the ligand makes ion pairs with Asp-184 and Glu-164. The ligand is then stabilized by stacking its ring with Trp-248 and the Cys-168 to Cys-180 disulfide bond <ref name="Yang">Yang, Fan, et al. "Structure, function and pharmacology of human itch receptor complexes." Nature, Nature Publishing Group, 17 November 2021, https://www.nature.com/articles/s41586-021-04077-y</ref>. | ||
===== Peptide ===== | ===== Peptide ===== | ||
| + | |||
<scene name='90/904328/Overview_x2_c_pt_2/1'>Cortistatin-14</scene> is one of the peptide ligands that binds to MRGPRX2. Cortistatin-14 interacts with the binding pocket through an <scene name='90/904328/Zic14_pt_2/1'>electrostatic</scene> interaction in sub-pocket 1 between Lys-3 on the peptide and Glu-164 and Asp-184 on MRGPRX2 <ref name="Cao"/>. Additionally, there are hydrophobic interactions in sub-pocket 2 between the peptide and the binding pocket due to the large hydrophobic amino acids on Cortistatin-14. [[Image: Peptide.PNG|250px|left|thumb|'''Figure 2''': Structure of Cortistatin-14 with resolved amino acids highlighted in green.<ref name="Yang">Yang, Fan, et al. "Structure, function and pharmacology of human itch receptor complexes." Nature, Nature Publishing Group, 17 November 2021, https://www.nature.com/articles/s41586-021-04077-y</ref>]] | <scene name='90/904328/Overview_x2_c_pt_2/1'>Cortistatin-14</scene> is one of the peptide ligands that binds to MRGPRX2. Cortistatin-14 interacts with the binding pocket through an <scene name='90/904328/Zic14_pt_2/1'>electrostatic</scene> interaction in sub-pocket 1 between Lys-3 on the peptide and Glu-164 and Asp-184 on MRGPRX2 <ref name="Cao"/>. Additionally, there are hydrophobic interactions in sub-pocket 2 between the peptide and the binding pocket due to the large hydrophobic amino acids on Cortistatin-14. [[Image: Peptide.PNG|250px|left|thumb|'''Figure 2''': Structure of Cortistatin-14 with resolved amino acids highlighted in green.<ref name="Yang">Yang, Fan, et al. "Structure, function and pharmacology of human itch receptor complexes." Nature, Nature Publishing Group, 17 November 2021, https://www.nature.com/articles/s41586-021-04077-y</ref>]] | ||
| Line 34: | Line 35: | ||
===== ''Toggle Switch'' ===== | ===== ''Toggle Switch'' ===== | ||
| - | In β2AR, and other Class A GPCRs, | + | In β2AR, and other Class A GPCRs, a “toggle switch” of <scene name='90/904328/B2artoggleswitchyes_pt_3/1'>Trp-286</scene> which limits the proximity of the TM helices as tryptophan sterically occludes tight interaction. This results in a deep binding pocket for ligand binding. In contrast, in MRGPRX2 Trp-286 is replaced by <scene name='90/904328/Toggle_switch_gly_pt_2/1'>Gly-236</scene> <ref name="Cao"/> <ref name="Yang"/>. Glycine is a much smaller amino acid and thus allows the helices to close the base of the binding pocket. This causes MRGPRX2 to have a much shallower binding site and allows more promiscuous ligand binding. This can be seen in a shorter distance from the toggle switch to the ligand in β2AR compared to MRGPRX2. |
===== ''PIF Motif'' ===== | ===== ''PIF Motif'' ===== | ||
| - | + | MRGPRX2 also differs from typical Class A GPCRs based on substitutions in the PIF/connector motif, which acts as a microswitch. PIF plays a role in connecting the binding pocket to conformational rearrangements required for receptor activation<ref name="Schonegge">Schonegge, Anne-Marie, et al. "Evolutionary action and structural basis of the allosteric switch controlling β2AR functional selectivity." Nature, Nature Publishing Group, 18 December 2017, https://www.nature.com/articles/s41467-017-02257-x</ref>. The PIF motif is located towards the base of the TM domains. In a Class A GPCR, like β2AR, the <scene name='90/904328/B2arpif_pt_2/1'>PIF motif</scene> consists of Phe-211, Ile-121, and Phe-282 on TM domains 5, 3, and 6, respectively. However, for MRGPRX2, this <scene name='90/904328/Mxpifnolabel_pt_2/1'>motif</scene> is replaced with Leu-194 on TM5, Leu-117 on TM3, and Phe-232 on TM6. | |
===== ''DRY Motif'' ===== | ===== ''DRY Motif'' ===== | ||
| Line 55: | Line 56: | ||
| + | == Clinical Relevance == | ||
| - | |||
| - | == Clinical Relevance == | ||
[[Image: Drugs.PNG|400px|right|thumb|'''Figure 4''': Structures of Dextromethorphan, Morphine, and Codeine.<ref name="Cao"/>]] | [[Image: Drugs.PNG|400px|right|thumb|'''Figure 4''': Structures of Dextromethorphan, Morphine, and Codeine.<ref name="Cao"/>]] | ||
| - | Many drugs | + | Many drugs activate MRGPRX2 as a side effect that causes the sensation of itchiness <ref name="Cao"/>. Among these drugs are morphine, codeine, and dextromethorphan.These drugs have a similar structure to that of (R)- ZINC-3573, introducing the idea of a similar binding mechanism <ref name="Babina"> Babina, M., et al. "MRGPRX2 Is the Codeine Receptor of Human Skin Mast Cells: Desensitization through β-Arrestin and Lack of Correlation with the FcεRI Pathway." Journal of Investigative Dermatology, 141(6), 1286-1296. https://doi.org/10.1016/j.jid.2020.09.017</ref>. |
Due to mutations in key structural features of typical Class A GPCRS, MRGPRX2, it is able to bind to a variety of substrates that then mediate the signaling pathway for the sensation of itching. | Due to mutations in key structural features of typical Class A GPCRS, MRGPRX2, it is able to bind to a variety of substrates that then mediate the signaling pathway for the sensation of itching. | ||
Revision as of 19:30, 7 April 2022
| This Sandbox is Reserved from February 28 through September 1, 2022 for use in the course CH462 Biochemistry II taught by R. Jeremy Johnson at the Butler University, Indianapolis, USA. This reservation includes Sandbox Reserved 1700 through Sandbox Reserved 1729. |
To get started:
More help: Help:Editing |
Human Itch GPCR
| |||||||||||
References
- ↑ Thal, David M., et al. "Structural insights into G-protein-coupled receptor allostery." Nature, Nature Publishing Group, 04 July 2018, https://www.nature.com/articles/s41586-018-0259-z
- ↑ 2.0 2.1 Zhang D, Zhao Q, Wu B. Structural Studies of G Protein-Coupled Receptors. Mol Cells. 2015 Oct;38(10):836-42. doi: 10.14348/molcells.2015.0263. Epub 2015, Oct 15. PMID:26467290 doi:http://dx.doi.org/10.14348/molcells.2015.0263
- ↑ 3.0 3.1 Zhou Q, Yang D, Wu M, Guo Y, Guo W, Zhong L, Cai X, Dai A, Jang W, Shakhnovich EI, Liu ZJ, Stevens RC, Lambert NA, Babu MM, Wang MW, Zhao S. Common activation mechanism of class A GPCRs. Elife. 2019 Dec 19;8. pii: 50279. doi: 10.7554/eLife.50279. PMID:31855179 doi:http://dx.doi.org/10.7554/eLife.50279
- ↑ 4.0 4.1 4.2 4.3 4.4 4.5 Cao, Can, et al. "Structure, function and pharmacology of human itch GPCRs." Nature, Nature Publishing Group, 17 November 2021, https://www.nature.com/articles/s41586-021-04126-6
- ↑ 5.0 5.1 5.2 5.3 5.4 5.5 Yang, Fan, et al. "Structure, function and pharmacology of human itch receptor complexes." Nature, Nature Publishing Group, 17 November 2021, https://www.nature.com/articles/s41586-021-04077-y
- ↑ 6.0 6.1 Schonegge, Anne-Marie, et al. "Evolutionary action and structural basis of the allosteric switch controlling β2AR functional selectivity." Nature, Nature Publishing Group, 18 December 2017, https://www.nature.com/articles/s41467-017-02257-x
- ↑ Sandoval, A., et al. "The Molecular Switching Mechanism at the Conserved D(E)RY Motif in Class-A GPCRs." Biophysical journal, 111(1), 79-89. https://doi.org/10.1016/j.bpj.2016.06.004
- ↑ Katritch V, Fenalti G, Abola EE, Roth BL, Cherezov V, Stevens RC. Allosteric sodium in class A GPCR signaling. Trends Biochem Sci. 2014 May;39(5):233-44. doi: 10.1016/j.tibs.2014.03.002. Epub , 2014 Apr 21. PMID:24767681 doi:http://dx.doi.org/10.1016/j.tibs.2014.03.002
- ↑ Babina, M., et al. "MRGPRX2 Is the Codeine Receptor of Human Skin Mast Cells: Desensitization through β-Arrestin and Lack of Correlation with the FcεRI Pathway." Journal of Investigative Dermatology, 141(6), 1286-1296. https://doi.org/10.1016/j.jid.2020.09.017
